Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from TempraMed Technologies Ltd. ( (TSE:VIVI) ) is now available.
TempraMed reported a transformative 2025 marked by rapid international expansion, accelerating market adoption of its VIVI devices, and strengthening of its scientific and intellectual property foundations as it positions itself for global commercialization. The company entered key distribution partnerships in Israel, Turkey, and Western Europe, secured a major agreement with Maccabi Healthcare Services, launched the VIVI Cap Smart digital-health device with a subscription-based model, and expanded manufacturing capacity with a new Florida facility to lower costs and support anticipated demand, moves that collectively enhance its competitive moat and readiness to scale across institutional healthcare channels in 2026.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a medical technology company focused on transforming how temperature-sensitive injectable medications are stored and managed. Through its patented VIVI product line, including VIVI Cap and VIVI EPI, the company offers non-powered solutions that protect medications from real-world heat and cold exposure without refrigeration or external power, targeting patients, pharmacies, and healthcare systems in high-need markets such as diabetes care.
Average Trading Volume: 33,407
See more insights into VIVI stock on TipRanks’ Stock Analysis page.